CytoDyn (CYDY) Stock Chart & Stock Price History $0.30 0.00 (0.00%) As of 08/22/2025 03:59 PM Eastern Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock CytoDyn Stock Price Performance The CytoDyn (CYDY) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 128.81%, with a year-to-date return of 170.74%. In the past month, the stock has increased 1.19%, reflecting recent market activity. As of the latest close, CytoDyn traded at $0.30 with a market cap of $372.45 million and volume of 2.12 million shares. Five years ago, the stock traded at $3.84, representing a 92.27% decrease over that period. At the time, it had a market cap of $1.95 billion and a volume of 9.68 million shares. Receive CYDY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+2.41%1 Month Performance+1.19%3 Month Performance-12.65%Year-To-Date Performance+170.74%1 Year Performance+128.81%5 Year Performance-92.27% CYDY Stock Chart for Sunday, August, 24, 2025 CYDY Chart by TradingView CytoDyn Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$0.30$0.30$0.31$0.302.12 million shs$372.45 million08/21/2025$0.29$0.30+2.41%$0.30$0.282.22 million shs$372.45 million08/20/2025$0.29$0.29$0.29$0.28929,223 shs$363.67 million08/19/2025$0.29$0.29+0.97%$0.30$0.28778,302 shs$363.67 million08/18/2025$0.28$0.29+4.44%$0.30$0.272.06 million shs$360.16 million08/15/2025$0.27$0.28+2.38%$0.29$0.262.55 million shs$344.86 million08/14/2025$0.26$0.27+3.31%$0.27$0.251.11 million shs$336.83 million08/13/2025$0.24$0.26+8.33%$0.27$0.232.83 million shs$326.02 million08/12/2025$0.24$0.24+0.04%$0.25$0.222.18 million shs$300.94 million08/11/2025$0.26$0.24-6.83%$0.26$0.232.15 million shs$300.82 million Get the Latest News and Ratings for CYDY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$0.26$0.26-1.72%$0.27$0.251.32 million shs$322.89 million08/07/2025$0.27$0.26-2.60%$0.29$0.261.85 million shs$328.53 million08/06/2025$0.26$0.27+2.67%$0.27$0.261.17 million shs$337.31 million08/05/2025$0.28$0.26-5.42%$0.28$0.26819,541 shs$328.53 million08/04/2025$0.29$0.28-5.33%$0.30$0.271.47 million shs$347.34 million08/01/2025$0.29$0.29+0.90%$0.30$0.29887,595 shs$366.90 million07/31/2025$0.29$0.29+1.54%$0.30$0.28773,057 shs$357.44 million07/30/2025$0.27$0.29+4.62%$0.29$0.271.08 million shs$357.44 million07/29/2025$0.28$0.27-4.08%$0.29$0.262.22 million shs$341.67 million07/28/2025$0.30$0.28-4.05%$0.32$0.281.36 million shs$356.19 million07/25/2025$0.29$0.30+1.06%$0.30$0.281.16 million shs$371.21 million07/24/2025$0.29$0.29+1.21%$0.31$0.28565,109 shs$367.32 million07/23/2025$0.29$0.29-1.43%$0.31$0.281.36 million shs$362.94 million Related Companies CALT Stock Chart XERS Stock Chart PAHC Stock Chart NTLA Stock Chart COLL Stock Chart LENZ Stock Chart PHVS Stock Chart CLXPF Stock Chart SNDX Stock Chart CRON Stock Chart Receive CYDY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:CYDY) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access